- Research & Development
- GMP Contract Manufacturing
- Allergen Shop
The only specific and disease-modifying form of therapy is allergen-specific immunotherapy (SIT) , a therapeutic vaccination based on the administration of the disease eliciting allergens to the allergic patient. SIT using extracts from natural allergen sources was first described by Noon et al. in 1911. Vaccination with allergen extracts is frequently accompanied by unwanted side effects which may be life-threatening such as anaphylactic shock.
Therefore, the majority of allergic patients today are still treated with pharmacotherapy (e.g. antihistamines) which alleviates the symptoms of allergy but cannot stop the progression of the disease (allergic march). There is an urgent medical need for innovative products for SIT with an advanced safety profile and defined/controlled composition to meet state-of-the-art pharmaceutical standards.